top of page
Cytovia has been built through multiple collaborations with academic researchers, leading medical centers, and strategic partners. We aim to accelerate the transformation of cancer therapy and develop first-in-class products in areas of major unmet medical need.
As Cytovia matures its gene-edited iNK/CAR-iNK and Flex-NK™ bispecific antibody platforms, we are open to research partnerships and co-development with academic institutions and industry partners to broaden the use of NK Cell Therapies.
bottom of page